GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Implantica AG (STU:8IM1) » Definitions » Capex-to-Operating-Income

Implantica AG (STU:8IM1) Capex-to-Operating-Income : 0.00 (As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Implantica AG Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Implantica AG's Capital Expenditure for the six months ended in . 20 was €0.00 Mil. Its Operating Income for the six months ended in . 20 was €0.00 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Implantica AG Capex-to-Operating-Income Historical Data

The historical data trend for Implantica AG's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Implantica AG Capex-to-Operating-Income Chart

Implantica AG Annual Data
Trend
Capex-to-Operating-Income

Implantica AG Semi-Annual Data
Capex-to-Operating-Income

Competitive Comparison of Implantica AG's Capex-to-Operating-Income

For the Medical Devices subindustry, Implantica AG's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Implantica AG's Capex-to-Operating-Income Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Implantica AG's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Implantica AG's Capex-to-Operating-Income falls into.


;
;

Implantica AG Capex-to-Operating-Income Calculation

Implantica AG's Capex-to-Operating-Income for the fiscal year that ended in . 20 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- () /
=N/A

Implantica AG's Capex-to-Operating-Income for the quarter that ended in . 20 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- () /
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Implantica AG  (STU:8IM1) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Implantica AG Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Implantica AG's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Implantica AG Business Description

Comparable Companies
Traded in Other Exchanges
Address
Aeulestrasse 45, Vaduz, LIE, 9490
Implantica AG is a medtech group providing effective care for serious health conditions and improving patients' quality of life by bringing advanced technology into the body. The therapies Implantica develops are based on implants that are medical devices inserted into the patient's body and are intended to remain in place permanently or semi-permanently, using electrical power provided by a battery. The company has developed a broad, patent-protected, product pipeline based partly on its two platform technologies. Its lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results.

Implantica AG Headlines

No Headlines